Federal Judge Delays U.S. Marijuana Decision After Report Exposes Missing Agency Rules

Federal Judge Delays U.S. Marijuana Decision After Report Exposes Missing Agency Rules

2026-10-23 politics

Washington, Friday, 23 October 2026.
A federal judge postponed the marijuana rescheduling recommendation until after the midterm elections after admitting a watchdog report revealing the government lacks written standards for drug evaluation.

Judicial Delay and Procedural Scrutiny

On October 22, 2026, DEA Chief Administrative Law Judge Derek C. Julius formally admitted a Government Accountability Office report into the marijuana rescheduling hearing record while denying requests to reopen the hearing for new testimony [1][2]. The judge ruled that the existing record, comprising over 2,500 pages of witness testimony, was sufficient for evaluation, though he ordered parties to submit limited briefs on the GAO report’s weight by October 29, 2026 [2][5]. This decision effectively postpones the final nonbinding recommendation on marijuana rescheduling until after the upcoming midterm elections, extending a period of regulatory limbo for the sector [1][5].

Regulatory Context and Precedent

This development follows a series of restrictive regulatory moves, including the October 2026 denial of a federal bulk-manufacturing license for Colorado-based MedPharm Research by DEA Administrator Terrance Cole [8]. That ruling established that participation in state-regulated recreational markets remains inconsistent with federal Controlled Substances Act requirements, reinforcing the divide between state and federal legality [8]. Investors and operators continue to navigate this fragmented landscape, where state authorization does not guarantee federal compliance or access to traditional banking structures [8].

GAO Findings on Agency Protocols

The admitted GAO report, released on September 23, 2026, identified significant procedural gaps, noting that neither the DEA nor the FDA possesses comprehensive written policies for drug-scheduling decisions [1][6]. While the agencies’ processes have aligned with Department of Health and Human Services recommendations, the lack of documented standards raises questions about transparency and consistency in evaluation [1][6]. Industry leaders argue that decisions affecting public health and regulated businesses must be grounded in documented standards to ensure accountability [6].

Prior to the October 22 ruling, the DEA filed a brief on October 20, 2026, opposing opponents’ requests to reopen the hearing for document discovery, labeling the move an “obvious fishing expedition” [3][7]. The agency argued that the Administrative Procedure Act does not support further record supplementation following the closure of testimony, asserting that the GAO report identifies the absence of records rather than their exclusion [3][4]. Despite this opposition, the judge permitted limited briefing to determine if the identified procedural gaps jeopardize the rescheduling proposal [2][5].

Briefing Schedule and Future Deadlines

The legal proceeding is currently stayed under a limited briefing schedule, with initial briefs due on October 29, 2026, and reply briefs due by November 5, 2026 [1][5]. Judge Julius specified that these briefs must be narrowly tailored to the weight of the GAO report and its potential effect on the current rescheduling matter [2][5]. Once the briefing period concludes, the stay will automatically expire, allowing the judge to certify the record and issue a recommendation [1][5].

Market Implications and Investor Uncertainty

The continued delay maintains policy uncertainty for cannabis operators and institutional investors, directly impacting potential tax relief under Section 280E and corporate restructuring plans [1][6]. Duane Boise, President and CEO of MMJ International Holdings, noted that people expect government decisions with major consequences to follow clear, consistent rules [1][6]. As the industry awaits further clarity, the distinction between state authorization and federal legality remains a critical risk factor for capital allocation [8].

Sources


DEA Hearing Marijuana Rescheduling